Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Net Margin (2016 - 2025)

Historic Net Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to 7.53%.

  • Ptc Therapeutics' Net Margin rose 617300.0% to 7.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.25%, marking a year-over-year increase of 1057300.0%. This contributed to the annual value of 45.03% for FY2024, which is 217800.0% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Net Margin of 7.53% as of Q3 2025, which was up 617300.0% from 36.25% recorded in Q2 2025.
  • Ptc Therapeutics' Net Margin's 5-year high stood at 73.68% during Q1 2025, with a 5-year trough of 109.07% in Q1 2021.
  • Its 5-year average for Net Margin is 60.07%, with a median of 65.35% in 2023.
  • Over the last 5 years, Ptc Therapeutics' Net Margin had its largest YoY gain of 1396800bps in 2021, and its largest YoY loss of -374500bps in 2021.
  • Over the past 5 years, Ptc Therapeutics' Net Margin (Quarter) stood at 86.71% in 2021, then dropped by -18bps to 102.08% in 2022, then skyrocketed by 50bps to 50.74% in 2023, then soared by 39bps to 30.91% in 2024, then skyrocketed by 124bps to 7.53% in 2025.
  • Its Net Margin was 7.53% in Q3 2025, compared to 36.25% in Q2 2025 and 73.68% in Q1 2025.